Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Toliodium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 6/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.36 |
| ▸ | HTR3B | O95264 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.36 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toliodium SCHEMBL125171 | 0.97 | ACHE (0.57) | ACHETDP1ALDH1A1CA2CA1 | |
| Toliodium SCHEMBL5408779 | 0.93 | ACHE (0.53) | ACHETDP1ALDH1A1CA2CA1 | |
| Toliodium SCHEMBL7743288 | 0.93 | ACHE (0.53) | ACHETDP1ALDH1A1CA2CA1 | |
| Toliodium SCHEMBL9296014 | 0.93 | ACHE (0.53) | ACHETDP1ALDH1A1CA2CA1 | |
| Toliodium SCHEMBL125044 | 0.88 | ACHE (0.47) | ACHETDP1ALDH1A1CA2CA1 | |
| SCHEMBL10022958 | 0.88 | ACHE (0.47) | ACHETDP1ALDH1A1CA2CA1 | |
| Toliodium SCHEMBL125045 | 0.88 | ACHE (0.47) | ACHETDP1ALDH1A1CA2CA1 | |
| Toliodium SCHEMBL31513889 | 0.85 | ACHE (0.44) | ACHETDP1ALDH1A1CA2CA1 | |
| Toliodium SCHEMBL29443426 | 0.85 | ACHE (0.44) | ACHETDP1ALDH1A1CA2CA1 | |
| Toliodium SCHEMBL1134117 | 0.85 | ACHE (0.44) | ACHETDP1ALDH1A1CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017879-A1 | COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION THEREOF | Bio Logic Crop Science S.L. (ES) | 2025-01-16 | — | — | US | disclosed |
| EP-4427745-A1 | COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION METHOD THEREOF | Bio Logic Crop Science, S.L. (ES) | 2024-09-11 | — | — | EP | disclosed |
| US-11766364-B2 | Wound closure systems for reducing surgical site infections comprising incision drapes filled with releasable antimicrobial agents | ETHICON, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11452641-B2 | Wound closure systems for reducing surgical site infections comprising incision drapes filled with releasable antimicrobial agents | ETHICON, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| US-20220296423-A1 | Wound Closure Systems for Reducing Surgical Site Infections Comprising Incision Drapes Filled with Releasable Antimicrobial Agents | ETHICON, INC. (US) | 2022-09-22 | — | — | US | disclosed |
| US-20220296422-A1 | Wound Closure Systems for Reducing Surgical Site Infections Comprising Incision Drapes Filled with Releasable Antimicrobial Agents | ETHICON, INC. (US) | 2022-09-22 | — | — | US | disclosed |
| EP-3989865-A1 | WOUND CLOSURE SYSTEMS FOR REDUCING SURGICAL SITE INFECTIONS COMPRISING INCISION DRAPES FILLED WITH RELEASABLE ANTIMICROBIAL AGENTS | Ethicon, Inc (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-1682609-B1 | METHOD OF MODIFYING A FLUOROPOLYMER AND ARTICLES THEREBY | 3M INNOVATIVE PROPERTIES CO (US) | 2015-03-11 | — | — | EP | disclosed |
| EP-1752463-B1 | NOVEL FLUORINATED ALKYLFLUOROPHOSPHORIC ACID SALT OF ONIUM AND TRANSITION METAL COMPLEX | SAN APRO LTD (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-7709598-B2 | Fluorinated alkyl fluorophoshoric acid salts of onium and transition metal complex | SAN-APRO LIMITED (JP) | 2010-05-04 | — | — | US | disclosed |
| US-4912018-A | High resolution photoresist based on imide containing polymers | HOECHST CELANESE CORPORATION (US) | 1990-03-27 | — | — | US | disclosed |
| US-4837124-A | High resolution photoresist of imide containing polymers | HOECHST CELANESE CORPORATION (US) | 1989-06-06 | — | — | US | disclosed |
| EP-0234327-A2 | High resolution photoresist of imide containing polymers | HOECHST CELANESE CORPORATION (US) | 1987-09-02 | — | — | EP | disclosed |
| US-4439517-A | Process for the formation of images with epoxide resin | CIBA-GEIGY CORPORATION (US) | 1984-03-27 | — | — | US | disclosed |
| US-4250311-A | PHOSPHORUS, ARSENIC, ANTIMONY | GENERAL ELECTRIC COMPANY (US) | 1981-02-10 | — | — | US | disclosed |
| US-4234732-A | BENZOYLMETHYLQUINOLINIUM HEXAFLUOROPHOSPHATE, CURING POLYEPOXIDES | GENERAL ELECTRIC COMPANY (US) | 1980-11-18 | — | — | US | disclosed |
| US-4219654-A | FOR PRODUCING ULTRAVIOLET LIGHT CURED RESINS | GENERAL ELECTRIC COMPANY (US) | 1980-08-26 | — | — | US | disclosed |
| US-4136102-A | PHOTOINITIATORS | GENERAL ELECTRIC COMPANY (US) | 1979-01-23 | — | — | US | disclosed |
| US-4006180-A | DIURETIC | MERCK & CO., INC. (US) | 1977-02-01 | — | — | US | disclosed |
| US-3966966-A | DIURETICS | MERCK & CO., INC. (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017879-A1 | COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION THEREOF | SARS1, ACE2, PHOSPHO1 | ACHE 563/4885TDP1 2824/4885ALDH1A1 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.